Update on Clostridium difficile infection

被引:51
作者
O'Donoghue, Caoilfhionn [1 ]
Kyne, Lorraine [1 ,2 ]
机构
[1] Mater Misericordiae Univ Hosp, Dept Med Older Person, Dublin 7, Ireland
[2] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland
关键词
Clostridium difficile; fidaxomicin; hypervirulent strains; monoclonal antibodies; INFLAMMATORY-BOWEL-DISEASE; POLYMERASE-CHAIN-REACTION; PROTON PUMP INHIBITORS; PCR RIBOTYPE 027; RISK-FACTOR; TOXINOTYPE-V; CLINICAL MICROBIOLOGY; EUROPEAN-SOCIETY; NORTH-AMERICA; DIARRHEA;
D O I
10.1097/MOG.0b013e3283411634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose of review This review summarizes the most recent epidemiological data and advances in research into the pathogenesis, diagnosis and treatment of Clostridium difficile infection (CDI). Recent findings The epidemiology of CDI has changed with the emergence of hypervirulent strains. CDI rates have increased in the community, in children and in patients with inflammatory bowel disease. Although the North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis group BI, PCR ribotype 027 (NAP1/BI/027) strain remains prevalent in North America, surveillance suggests that it is decreasing in Europe. A similar strain, PCR ribotype 078, is emerging which is associated with community-associated CDI and has been isolated in animals and food products. The Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America have published new guidelines on the epidemiology, diagnosis, treatment, infection control and environmental management of C. difficile. Several novel therapies for CDI are at different stages of development. There have been promising trial results with fidaxomicin, a novel antibiotic for the treatment of CDI and monoclonal antibodies against toxins A and B, which have been shown to significantly reduce CDI recurrence rates. Summary Major advances have been made in our understanding of the spread and pathogenesis of C. difficile and new treatment options are becoming available.
引用
收藏
页码:38 / 47
页数:10
相关论文
共 120 条
[1]  
Abougergi Marwan S, 2010, J Hosp Med, V5, pE1, DOI 10.1002/jhm.542
[2]   Increased sporulation rate of epidemic clostridium difficile type 027/NAP1 [J].
Akerlund, Thomas ;
Persson, Ingela ;
Unemo, Magnus ;
Noren, Torbjoern ;
Svenungsson, Bo ;
Wullt, Marlene ;
Burman, Lars G. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) :1530-1533
[3]  
ANANTHAKRISHNAN AN, 2010, MED CLIN N AM, V38, P711
[4]  
[Anonymous], INFLAMM BOWEL DIS
[5]   Prospective assessment of two-stage testing for Clostridium difficile [J].
Arnold, A. ;
Pope, C. ;
Bray, S. ;
Riley, P. ;
Breathnach, A. ;
Krishna, S. ;
Planche, T. .
JOURNAL OF HOSPITAL INFECTION, 2010, 76 (01) :18-22
[6]   Treatment of Clostridium difficile-associated disease:: old therapies and new strategies [J].
Aslam, S ;
Hamill, R ;
Musher, DM .
LANCET INFECTIOUS DISEASES, 2005, 5 (09) :549-557
[7]   Fecal bacteriotherapy for recurrent Clostridium difficile infection [J].
Bakken, Johan S. .
ANAEROBE, 2009, 15 (06) :285-289
[8]   Relatedness of Human and Animal Clostridium difficile PCR Ribotype 078 Isolates Determined on the Basis of Multilocus Variable-Number Tandem-Repeat Analysis and Tetracycline Resistance [J].
Bakker, D. ;
Corver, J. ;
Harmanus, C. ;
Goorhuis, A. ;
Keessen, E. C. ;
Fawley, W. N. ;
Wilcox, M. H. ;
Kuijper, E. J. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (10) :3744-3749
[9]   Clinical features of Clostridium difficile-associated infections and molecular characterization of strains:: Results of a retrospective study, 2000-2004 [J].
Barbut, Frederic ;
Gariazzo, Beatrice ;
Bonne, Laetitia ;
Lalande, Valerie ;
Burghoffer, Beatrice ;
Luiuz, Ralucca ;
Petit, Jean-Claude .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (02) :131-139
[10]  
BARTLETT JG, 1984, DM-DIS MON, V30, P1